Publications
Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. Journal of the National Cancer Institute. 2013. PMID: 23425564
Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2013. PMID: 23431193
Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M, Krampf MR, Jones CD, Waqar AN, Faham M, Zehnder JL, Miklos DB. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia. 2013. PMID: 23419792
Kaplan CP, Nápoles AM, Dohan D, Shelley Hwang E, Melisko M, Nickleach D, Quinn JA, Haas J. Clinical trial discussion, referral, and recruitment: physician, patient, and system factors. Volume 24 of Issue 5 Cancer causes & control : CCC. 2013. PMID: 23420328
Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. Journal of the National Cancer Institute. 2013. PMID: 23411591
Komanduri KV. Pharmacists and physicians in hematopoietic stem cell transplantation: advances and opportunities to use collaborative practice agreements to improve care. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013. PMID: 23416093
Vijayaraghavan M, Penko J, Bangsberg DR, Miaskowski C, Kushel MB. Opioid analgesic misuse in a community-based cohort of HIV-infected indigent adults. JAMA internal medicine. 2013. PMID: 23319013
Datta D, McClendon CL, Jacobson MP, Wells JA. Substrate and inhibitor-induced dimerization and cooperativity in caspase-1 but not caspase-3. The Journal of biological chemistry. 2013. PMID: 23386603
Grunberg SM, Slusher B, Rugo HS. Emerging treatments in chemotherapy-induced nausea and vomiting. Clinical advances in hematology & oncology : H&O. 2013. PMID: 23598819
Bergsland EK. Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors. Seminars in oncology. 2013. PMID: 23391108
Jesse W. Keller, Lloyd E. Damon, Lawrence D. Kaplan, Thomas G. Martin, Jeffrey L. Wolf, Weiyun Z. Ai, Charalambos Andreadis, Jeffrey M. Venstrom, Catherine C. Smith, Karin M.L. Gaensler, Jimmy Hwang, Rebecca L. Olin. Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Is Predictive of Serious Adverse Events and Overall Survival in Older Allogeneic Transplant Recipients. Biology of Blood and Marrow Transplantation. 2013. PMID:
Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2013. PMID: 23411381
Bergsland EK. The evolving landscape of neuroendocrine tumors. Seminars in oncology. 2013. PMID: 23391109
Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. The Journal of pathology. 2013. PMID: 23165508
Hrustanovic G, Lee BJ, Bivona TG. Mechanisms of resistance to EGFR targeted therapies. Cancer biology & therapy. 2013. PMID: 23358468
Goodwin PJ, Ballman KV, Small EJ, Cannistra SA. Evaluation of treatment benefit in Journal of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013. PMID: 23358984
Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nature cell biology. 2013. PMID: 23354167
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science (New York, N.Y.). 2013. PMID: 23348506
Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013. PMID: 23344262
Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhao X, Winter JN, Zhang M, Li L, Møller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013. PMID: 23343832